Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2018

Open Access 01-12-2018 | Research

The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation

Authors: Martin H. Umbehr, Lucas M. Bachmann, Cedric Poyet, Peter Hammerer, Johann Steurer, Milo A. Puhan, Anja Frei

Published in: Health and Quality of Life Outcomes | Issue 1/2018

Login to get access

Abstract

Background

No official German translation exists for the 50-item Expanded Prostate Cancer Index Composite (EPIC), and no minimal important difference (MID) has been established yet. The aim of the study was to translate and validate a German version of the EPIC with cultural adaptation to the different German speaking countries and to establish the MID.

Methods

We translated and culturally adapted the EPIC into German. For validation, we included a consecutive subsample of 92 patients with localized prostate cancer undergoing radical prostatectomy who participated the Prostate Cancer Outcomes Cohort. Baseline and follow-up assessments took place before and six weeks after prostatectomy in 2010 and 2011.
We assessed the EPIC, EORTC QLQ-PR25, Feeling Thermometer, SF-36 and a global rating of health state change variable. We calculated the internal consistency, test-retest reliability, construct validity, responsiveness and MID.

Results

For most EPIC domains and subscales, our a priori defined criteria for reliability were fulfilled (construct reliability: Cronbach’s alpha 0.7–0.9; test-retest reliability: intraclass-correlation coefficient ≥ 0.7). Cross-sectional and longitudinal correlations between EPIC and EORTC QLQ-PR25 domains ranged from 0.14–0.79, and 0.06–0.5 and 0.08–0.72 for Feeling Thermometer and SF-36, respectively. We established MID values of 10, 4, 12, and 6 for the urinary, bowel, sexual and hormonal domain.

Conclusion

The German version of the EPIC is reliable, responsive and valid to measure HRQL in prostate cancer patients and is now available in German language. With the suggested MID we provide interpretation to what extent changes in HRQL are clinically relevant for patients. Hence, study results are of interest beyond German speaking countries.
Appendix
Available only for authorised users
Literature
1.
go back to reference Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-Raspall R, Serraino D, et al. Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: Results from the EUROCARE-5 study. Eur J Cancer. 2015;51:2206–16.CrossRefPubMed Trama A, Foschi R, Larrañaga N, Sant M, Fuentes-Raspall R, Serraino D, et al. Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: Results from the EUROCARE-5 study. Eur J Cancer. 2015;51:2206–16.CrossRefPubMed
2.
go back to reference Bill-Axelson A, Garmo H, Holmberg L, Johansson J-E, Adami H-O, Steineck G, et al. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol. 2013;64:920–8.CrossRefPubMed Bill-Axelson A, Garmo H, Holmberg L, Johansson J-E, Adami H-O, Steineck G, et al. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol. 2013;64:920–8.CrossRefPubMed
3.
go back to reference Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.CrossRefPubMed Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.CrossRefPubMed
4.
go back to reference Harrington S, Lee J, Colon G, Alappattu M. Oncology section EDGE task force on prostate cancer: A systematic review of outcome measures for health-related quality of life. Rehabil Oncol. 2016;34:27–35.PubMedPubMedCentral Harrington S, Lee J, Colon G, Alappattu M. Oncology section EDGE task force on prostate cancer: A systematic review of outcome measures for health-related quality of life. Rehabil Oncol. 2016;34:27–35.PubMedPubMedCentral
5.
go back to reference Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.CrossRefPubMed Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.CrossRefPubMed
6.
go back to reference Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–12.CrossRefPubMed Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36:1002–12.CrossRefPubMed
7.
go back to reference Chung KJ, Kim JJ, Lim SH, Kim TH, Han DH, Lee SW. Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment. Korean J Urol. 2010;51:601–12.CrossRefPubMedPubMedCentral Chung KJ, Kim JJ, Lim SH, Kim TH, Han DH, Lee SW. Development and validation of the korean version of expanded prostate cancer index composite: questionnaire assessing health-related quality of life after prostate cancer treatment. Korean J Urol. 2010;51:601–12.CrossRefPubMedPubMedCentral
8.
go back to reference Takegami M, Suzukamo Y, Sanda MG, Kamoto T, Namiki S, Arai Y, et al. The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC). Japanese J Urol. 2005;96:657–69.CrossRef Takegami M, Suzukamo Y, Sanda MG, Kamoto T, Namiki S, Arai Y, et al. The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC). Japanese J Urol. 2005;96:657–69.CrossRef
9.
go back to reference Alves E, Medina R, Andreoni C. Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy. Int Braz J Urol. 2013;39:344–52. Alves E, Medina R, Andreoni C. Validation of the Brazilian version of the Expanded Prostate Cancer Index Composite (EPIC) for patients submitted to radical prostatectomy. Int Braz J Urol. 2013;39:344–52.
10.
go back to reference Ferrer M, Garin O, Pera J, Prats JM, Mendivil J, Alonso J, et al. Evaluation of the quality of life of patients with localizad prostate cancer: validation of the Spanish version of the EPIC. Med Clínica. 2009;132:128–35.CrossRef Ferrer M, Garin O, Pera J, Prats JM, Mendivil J, Alonso J, et al. Evaluation of the quality of life of patients with localizad prostate cancer: validation of the Spanish version of the EPIC. Med Clínica. 2009;132:128–35.CrossRef
11.
go back to reference Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245–50.CrossRefPubMedPubMedCentral Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76:1245–50.CrossRefPubMedPubMedCentral
12.
go back to reference Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011;186:865–72.CrossRefPubMed Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011;186:865–72.CrossRefPubMed
13.
go back to reference van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24.CrossRefPubMed van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24.CrossRefPubMed
14.
go back to reference Beyer B, Huland H, Feick G, Graefen M. Expanded prostate cancer index composite" (EPIC-26): Results of functional treatment in patients with localized prostate cancer. Urologe. 2015;54:1591–5.CrossRefPubMed Beyer B, Huland H, Feick G, Graefen M. Expanded prostate cancer index composite" (EPIC-26): Results of functional treatment in patients with localized prostate cancer. Urologe. 2015;54:1591–5.CrossRefPubMed
15.
go back to reference Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: report of the ispor task force for translation and cultural adaptation. Value Heal. 2005;8:94–104.CrossRef Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al. Principles of good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: report of the ispor task force for translation and cultural adaptation. Value Heal. 2005;8:94–104.CrossRef
16.
17.
go back to reference QL Coordinator. EORTC QLQ-C30 Scoring Manual 2001. QL Coordinator. EORTC QLQ-C30 Scoring Manual 2001.
18.
go back to reference Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.CrossRefPubMed Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.CrossRefPubMed
19.
go back to reference Devlin NJ, Krabbe PFM. The development of new research methods for the valuation of EQ-5D-5L. Eur J Heal Econ HEPAC Heal Econ Prev Care. 2013;14(Suppl 1):S1–3. Devlin NJ, Krabbe PFM. The development of new research methods for the valuation of EQ-5D-5L. Eur J Heal Econ HEPAC Heal Econ Prev Care. 2013;14(Suppl 1):S1–3.
20.
go back to reference Puhan MA, Behnke M, Devereaux PJ, Montori VM, Braendli O, Frey M, et al. Measurement of agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians--a prospective study. Respir Med. 2004;98:1195–202.CrossRefPubMed Puhan MA, Behnke M, Devereaux PJ, Montori VM, Braendli O, Frey M, et al. Measurement of agreement on health-related quality of life changes in response to respiratory rehabilitation by patients and physicians--a prospective study. Respir Med. 2004;98:1195–202.CrossRefPubMed
21.
go back to reference Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St. George’s Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol. 2003;56:1170–6.CrossRefPubMed Schunemann HJ, Griffith L, Jaeschke R, Goldstein R, Stubbing D, Guyatt GH. Evaluation of the minimal important difference for the feeling thermometer and the St. George’s Respiratory Questionnaire in patients with chronic airflow obstruction. J Clin Epidemiol. 2003;56:1170–6.CrossRefPubMed
22.
go back to reference Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed
23.
go back to reference Ware JE. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25:2130–9. Ware JE. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25:2130–9.
24.
go back to reference Jayadevappa R, Malkowicz SB, Wittink M, Wein AJ, Chhatre S. Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. Health Serv Res. 2012;47:1902–25.CrossRefPubMedPubMedCentral Jayadevappa R, Malkowicz SB, Wittink M, Wein AJ, Chhatre S. Comparison of distribution- and anchor-based approaches to infer changes in health-related quality of life of prostate cancer survivors. Health Serv Res. 2012;47:1902–25.CrossRefPubMedPubMedCentral
25.
go back to reference Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials. 1991;12:142S–58S.CrossRefPubMed Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials. 1991;12:142S–58S.CrossRefPubMed
26.
go back to reference Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61:102–9.CrossRefPubMed Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61:102–9.CrossRefPubMed
27.
go back to reference StataCorp. Stata Statistical Software: Release 13. College Station: StataCorp LP; 2013. StataCorp. Stata Statistical Software: Release 13. College Station: StataCorp LP; 2013.
28.
go back to reference Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015;85:101–5.CrossRefPubMedPubMedCentral Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015;85:101–5.CrossRefPubMedPubMedCentral
29.
go back to reference Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, et al. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol. 2014;191:638–45.CrossRefPubMed Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, et al. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol. 2014;191:638–45.CrossRefPubMed
Metadata
Title
The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation
Authors
Martin H. Umbehr
Lucas M. Bachmann
Cedric Poyet
Peter Hammerer
Johann Steurer
Milo A. Puhan
Anja Frei
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2018
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-018-0859-1

Other articles of this Issue 1/2018

Health and Quality of Life Outcomes 1/2018 Go to the issue